Log in to save to my catalogue

Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease i...

Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease i...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_f4765b6429fd4f42acca9201ac81c886

Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma

About this item

Full title

Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma

Publisher

England: BioMed Central Ltd

Journal title

BMC cancer, 2020-06, Vol.20 (1), p.612-15, Article 612

Language

English

Formats

Publication information

Publisher

England: BioMed Central Ltd

More information

Scope and Contents

Contents

The clonoSEQ® Assay (Adaptive Biotechnologies Corporation, Seattle, USA) identifies and tracks unique disease-associated immunoglobulin (Ig) sequences by next-generation sequencing of IgH, IgK, and IgL rearrangements and IgH-BCL1/2 translocations in malignant B cells. Here, we describe studies to validate the analytical performance of the assay usi...

Alternative Titles

Full title

Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_f4765b6429fd4f42acca9201ac81c886

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_f4765b6429fd4f42acca9201ac81c886

Other Identifiers

ISSN

1471-2407

E-ISSN

1471-2407

DOI

10.1186/s12885-020-07077-9

How to access this item